-
Product Insights
Quarterly Savory Biscuits pricing trends in the United States
Consumers' preferences for stores are most heavily influenced by pricing and promotions, but brands and retailers continue to adjust prices and promotions based on insufficient information from expensive, drawn-out, and incomplete audits of rival techniques. Brands and retailers can benefit from the unique intelligence provided by GlobalData Ecommerce Price Tracker, covering millions of SKUs, to identify, anticipate, and implement important business choices. GlobalData's new report titled "Quarterly Savory Biscuits pricing trends in the United States" serves as a crucial resource...
-
Sector Analysis
Angelman Syndrome (AS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Angelman Syndrome Disorder Marketed and Pipeline Drugs Report Overview Angelman Syndrome (AS) is a genetic condition that affects the nervous system and causes severe physical disabilities, learning disabilities, motor dysfunction, seizure disorder, and often a happy, sociable disposition. A person with AS will have a near-normal life expectancy, but they will need support throughout their life. Some delayed development can be observed at ages 6–12 months, while other common symptoms usually occur before age three years. The Angelman Syndrome marketed...
-
Sector Analysis
Competitor Landscape: CKD-MBD
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the CKD-MBD market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
Competitor Landscape: Graft Versus Host Disease (GVHD)
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the graft versus host disease (GVHD) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
Competitor Landscape: Sjögren’s Syndrome
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Sjögren's Syndrome market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
Competitor Landscape: Systemic Sclerosis (Scleroderma)
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Systemic Sclerosis (Scleroderma) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
Competitor Landscape: Psoriasis
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Psoriasis (PsO) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
Competitor Landscape: Atopic Dermatitis
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Atopic Dermatitis (AD) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
Competitor Landscape: Rheumatoid Arthritis
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Rheumatoid Arthritis (RA) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
Competitor Landscape: Idiopathic Pulmonary Fibrosis (IPF)
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Idiopathic Pulmonary Fibrosis (IPF) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher